Estrella Immunopharma (ESLA) Common Equity (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Common Equity of -$5.3 million for Q1 2026, down 187.85% year-over-year from $6.0 million in Q1 2025, and up 49.16% quarter-over-quarter from -$10.4 million in Q4 2025.
Estrella Immunopharma (ESLA) Common Equity (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Common Equity for 6 consecutive years, with -$5.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 187.85% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$5.3 million (down 187.85% YoY), while the FY2025 annual figure was -$10.4 million, down 7312.12% from the prior year.
- Common Equity grew to -$5.3 million in Q1 2026 per ESLA's latest filing, from -$10.4 million in the prior quarter.
- Across five years, Common Equity topped out at $10.1 million in Q3 2023 and bottomed at -$11.7 million in Q2 2023.
- Historically, Common Equity has averaged -$2.0 million across 5 years, with a median of -$1.8 million in 2025.
- Annual changes were most pronounced in 2023 — Common Equity surged 363.43% — and 2025, when it plunged 7312.12%.
- Estrella Immunopharma's Common Equity stood at -$6.5 million in 2022, then jumped by 239.73% to $9.0 million in 2023, then slumped by 98.41% to $143731.0 in 2024, then slumped by 7312.12% to -$10.4 million in 2025, then soared by 49.16% to -$5.3 million in 2026.
- Business Quant data shows ESLA's Common Equity at -$5.3 million in Q1 2026, -$10.4 million in Q4 2025, and -$9.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | -7.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.43 Mn |
| Mar 31, 2026 | -5.27 Mn |
| Dec 31, 2025 | -10.37 Mn |
| Sep 30, 2025 | -9.84 Mn |
| Jun 30, 2025 | -6.09 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Dec 31, 2024 | 143,731.00 |
| Sep 30, 2024 | 746,286.00 |
| Jun 30, 2024 | 4.27 Mn |
| Mar 31, 2024 | 8.49 Mn |
| Dec 31, 2023 | 9.05 Mn |
| Sep 30, 2023 | 10.07 Mn |
| Jun 30, 2023 | -11.74 Mn |
| Mar 31, 2023 | -9.11 Mn |
| Dec 31, 2022 | -6.48 Mn |
| Sep 30, 2022 | -3.82 Mn |
| Jun 30, 2022 | -1.04 Mn |
| Mar 31, 2022 | -1.15 Mn |
| Dec 31, 2021 | -1.01 Mn |
| Sep 30, 2021 | -870,395.00 |